HIMS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Hims & Hers Health Inc is not a strong buy for a beginner, long-term investor at this moment. While the company has positive catalysts such as the FDA's peptide policy change and hedge fund buying, the stock is currently overbought (RSI at 85.889), and financial performance shows declining net income and EPS. Additionally, analysts' ratings are mixed with no clear consensus for strong upside potential. Given the user's scenario, it is better to hold off on buying until the stock stabilizes or shows clearer long-term growth potential.
The stock is currently overbought with an RSI of 85.889, indicating potential for a pullback. The MACD is positive and expanding, showing bullish momentum. Moving averages are converging, and the stock is trading near its resistance level (R1: 26.025, R2: 28.162).
FDA's decision to lift restrictions on peptides, opening new growth opportunities.
Hedge funds are actively buying, with a 211.82% increase in buying activity last quarter.
Retail sentiment is extremely bullish following FDA announcements.
Financial performance shows declining net income (-20.84% YoY) and EPS (-27.27% YoY).
Analysts' ratings are mixed, with several firms maintaining Neutral or Hold ratings.
The stock is overbought, suggesting limited immediate upside.
In Q4 2025, revenue increased by 28.41% YoY to $617.8 million. However, net income dropped by 20.84% YoY to $20.6 million, and EPS fell by 27.27% YoY to $0.08. Gross margin also declined by 6.34% YoY to 71.94%.
Analysts have mixed ratings on the stock. While Barclays raised the price target to $29 with an Overweight rating, other firms like BofA and TD Cowen maintain Neutral or Hold ratings. Recent price target changes range from $21 to $29, reflecting uncertainty about the company's growth trajectory.
